Hypothyroidism News and Research

RSS

Hypothyroidism occurs when the thyroid gland does not produce enough thyroid hormone to meet the body’s needs. Without enough thyroid hormone, many of the body’s functions slow down. About 5 percent of the U.S. population has hypothyroidism. Women are much more likely than men to develop hypothyroidism.

Janssen’s NUCYNTA ER tablets more effective in providing pain management in adults with DPN

Janssen Pharmaceuticals, Inc. today announced the results of an investigational Phase 3 study suggesting NUCYNTA ER (tapentadol) extended-release tablets were significantly more effective than placebo in providing pain management among adults with chronic moderate to severe, painful diabetic peripheral neuropathy.

18 May 2012

Pfizer fails to meet primary endpoint in TORISEL Phase 3 study for advanced RCC

Pfizer Inc announced that the Phase 3 INTORSECT (B1771003) study, evaluating TORISEL(temsirolimus) in patients with advanced renal cell carcinoma (RCC) whose disease had progressed on or after SUTENT (sunitinib malate) therapy, did not meet the primary endpoint of prolonging progression free survival (PFS) when compared to sorafenib.

16 May 2012

Five significant genetic associations for hypothyroidism found

Using its unique online research platform, 23andMe, a leading personal genetics company, has found five significant genetic associations for hypothyroidism in the largest known genome-wide association study of hypothyroidism conducted to date. The details of the study are now available online in the journal PLoS ONE.

9 Apr 2012

FDA denies AstraZeneca Citizen Petitions on SEROQUEL labeling

AstraZeneca today announced that on March 7, 2012, the Food and Drug Administration denied Citizen Petitions requesting that the FDA withhold finally approving any generic quetiapine product with labeling that omits certain hyperglycemia warning language that the FDA required AstraZeneca to include in the labeling for SEROQUEL (quetiapine fumarate) tablets and SEROQUEL XR (quetiapine fumarate) extended-release tablets.

12 Mar 2012

People with celiac disease are at risk for osteoporosis

People with celiac disease are at risk for osteoporosis, according to physicians at Loyola University Health System (LUHS). A 2009 New England Journal of Medicine study supports this correlation. Researchers believe that people with celiac disease may develop osteoporosis because their body poorly absorbs calcium and vitamin D, which are necessary for bone health.

22 Feb 2012

FDA extends Novartis' Gleevec label to three-year treatment in patients with KIT+ GIST after surgery

Novartis announced today that following a priority review, the US Food and Drug Administration has approved an update to the Gleevec (imatinib mesylate) tablets label to recommend 36 months of treatment after surgery for adult patients with KIT (CD117)-positive gastrointestinal stromal tumors (GIST) who met the risk of recurrence inclusion criteria of the pivotal trial.

1 Feb 2012

Exposure to iodinated contrast media may increase risk of hyperthyroidism

Exposure to iodinated contrast media during imaging procedures is associated with changes in thyroid function, and increased risk of developing hyperthyroidism, according to a report in the January 23 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.

24 Jan 2012

$Coexisting comorbidities increase treatment costs for older adults with hip fractures$

Coexisting comorbidities increase treatment costs for older adults with hip fractures

More than 250,000 hip fractures occur every year in the U.S., often resulting in hospitalization, surgery, nursing-home admission, long-term disability, and/or extended periods of rehabilitation. Independent existing medical conditions significantly increase the treatment cost and length of hospitalization for older adults who have sustained a hip fracture, according to a new study recently published in the Journal of Bone and Joint Surgery.

19 Jan 2012

Factors associated with increased risk of in-hospital falls after total hip or knee replacement surgery

Investigators from Hospital for Special Surgery have identified factors that are associated with an increased risk of in-hospital falls after total hip or knee replacement surgery.

5 Dec 2011

Novartis to showcase 160 presentations on breast cancer, hematological disease drugs at SABCS and ASH

Novartis Pharmaceuticals Corporation will showcase more than one hundred and sixty presentations on data from its robust oncology portfolio at two key medical congresses this month, demonstrating significant advances for patients with cancers and hematological diseases.

3 Dec 2011

EU's FP7 programme provides €6M grant for Thyroid Hormone Replacement for Subclinical Hypo-Thyroidism Trial

Dr Patricia Kearney, Department of Epidemiology & Public Health, UCC is one of a group of researchers from European Universities who will participate in a new research project investigating current treatment practices for people who suffer from a mildly underactive thyroid gland.

21 Nov 2011

FDA EMDAC votes to recommend approval of Merck's VYTORIN for pre-dialysis CKD

Merck, known as MSD outside the United States and Canada, announced today that the Endocrinologic and Metabolic Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) unanimously voted to recommend approval of Merck's VYTORIN (ezetimibe/simvastatin) for use in patients with pre-dialysis chronic kidney disease.

3 Nov 2011

Prescription drug shortages: Endocrine Society calls for mandatory reporting by manufacturers

The Executive Order President Obama issued Monday directing the U.S. Food and Drug Administration to take action to reduce prescription drug shortages is a commendable first step, but the White House could strengthen its directive and address the full scope of the problem by ordering mandatory reporting by manufacturers, which The Endocrine Society calls for in its Position Statement on drug shortages.

2 Nov 2011

BUSM professor delivers Van Meter Award Lecture at 81st ATA meeting

The American Thyroid Association (ATA) is proud to announce that Dr. Elizabeth Pearce, Associate Professor of Medicine at Boston University School of Medicine, today delivered the Van Meter Award Lecture at its 81st Annual Meeting, held October 26-30, Indian Wells, California.

1 Nov 2011

J&JPRD submits NUCYNTA ER sNDA to FDA for DPN associated neuropathic pain

Johnson & Johnson Pharmaceutical Research & Development, L.L.C. announced today that it has submitted a supplemental New Drug Application to the U.S. Food and Drug Administration for NUCYNTA ER (tapentadol) extended-release tablets, an oral analgesic, for the management of neuropathic pain associated with diabetic peripheral neuropathy in adults.

31 Oct 2011

UCLA professor to receive ATA's Sidney H. Ingbar Distinguished Lectureship Award

The American Thyroid Association's (ATA) Sidney H. Ingbar Distinguished Lectureship Award recognizes outstanding academic achievements in thyroidology. An honorarium is conferred each year at the ATA Annual Meeting to an established investigator who has made major contributions to thyroid-related research over many years.

28 Oct 2011

Over-the-counter 'thyroid support' supplements could be dangerous

People who use over-the-counter "thyroid support" supplements may be putting their health at risk, according to a study being presented at the annual meeting of the American Thyroid Association. The supplements contain varying amounts of two different kinds of thyroid hormones apparently derived in large part from chopped up animal thyroid glands, says the study's senior investigator, Victor Bernet, M.D., an endocrinologist at Mayo Clinic in Florida.

28 Oct 2011

Holtorf Medical Group opens new affiliate center in King of Prussia, Pennsylvania

Holtorf Medical Group, California's leading integrative, evidence-based medical facility, is pleased to announce the opening of its newest affiliate center, Garabedian Medical Clinic in King of Prussia, Pennsylvania.

24 Oct 2011

HHWC medical doctors provide insight into depression

A staggering 230 million antidepressant prescriptions are filled each year. Yet the face of depression does not always fit the mold: a successful career, loving spouse, wonderful children, seemingly good health and finances. From the outside life appears perfect, so why are Americans depressed?

15 Oct 2011

Merck receives FDA approval for JUVISYNC to treat type 2 diabetes

Merck, known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has approved JUVISYNC(sitagliptin and simvastatin), a new treatment for type 2 diabetes that combines the glucose-lowering medication sitagliptin, the active component of JANUVIA (sitagliptin), with the cholesterol-lowering medication ZOCOR.

10 Oct 2011